Abstract
Never having been an employee of the pharmaceutical industry, my approach is that of an outsider looking in, with all the advantages and disadvantages which that description entails. I shall try to avoid seeming just a voyeur or a eunuch giving lessons in the art of love and shall focus on what measures and approaches might maximise the public good as well as the ability of the drug industry to contribute to improvements in public health. Industry will continue to be our major source of important new medicines, so that its health and vigour are vital to the introduction of the new drugs so desperately needed to treat the sick.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
Reference
Baum, M. L., et al. (1981). New Engl. J. Med.,305, 795
Editor information
Copyright information
© 1983 The Royal Society of Medicine
About this chapter
Cite this chapter
Lasagna, L. (1983). How Much Regulation is Desirable in Industry?. In: L’etang, H. (eds) Regulation and Restraint in Contemporary Medicine in the UK and USA. Palgrave Macmillan, London. https://doi.org/10.1007/978-1-349-06501-1_17
Download citation
DOI: https://doi.org/10.1007/978-1-349-06501-1_17
Publisher Name: Palgrave Macmillan, London
Print ISBN: 978-1-349-06503-5
Online ISBN: 978-1-349-06501-1
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)